Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Mar;34(3):1112-1122.
doi: 10.1007/s00464-019-06858-z. Epub 2019 May 29.

Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry

Xavier Andújar  1   2 , Carme Loras  3   4 , Begoña González  5   2 , Milena Socarras  5   2 , Vicente Sanchiz  6 , Maia Boscà  6 , Eugeni Domenech  7 , Margalida Calafat  7 , Esther Rodríguez  8 , Beatriz Sicilia  9 , Xavier Calvet  10   2 , Jesús Barrio  11 , Jordi Guardiola  12 , Eva Iglesias  13 , María José Casanova  14   2 , Yolanda Ber  15 , David Monfort  16 , Antonio López-Sanromán  17 , Iago Rodríguez-Lago  18 , Luís Bujanda  19   2 , Lucía Márquez  20 , María Dolores Martín-Arranz  21 , Yamile Zabana  1   2 , Fernando Fernández-Bañares  1   2 , María Esteve  1   2 ; ENEIDA registry of GETECCU
Collaborators, Affiliations
Observational Study

Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry

Xavier Andújar et al. Surg Endosc. 2020 Mar.

Erratum in

Abstract

Background: There is no information regarding the outcome of Crohn's disease (CD) patients treated with endoscopic balloon dilation (EBD) in non-referral hospitals, nor on the efficacy of EBD in ulcerative colitis (UC). We report herein the results of the largest series published to date.

Aim: To assess the efficacy and safety of EBD for inflammatory bowel disease (IBD) stenosis performed in 19 hospitals with different levels of complexity and to determine factors related to therapeutic success.

Methods: We identified IBD patients undergoing EBD in the ENEIDA database. Efficacy of EBD was compared between CD and UC and between secondary and tertiary hospitals. Predictive factors of therapeutic success were assessed with multivariate analysis.

Results: Four-hundred dilations (41.2% anastomotic) were performed in 187 IBD patients (13 UC/Indeterminate colitis). Technical and therapeutic success per dilation was achieved in 79.5% and 55.3%, respectively. Therapeutic success per patient was achieved in 78.1% of cases (median follow-up: 40 months) with 49.7% requiring more than one dilation. No differences related to either diagnosis or hospital complexity was found. Technical success [OR 4.12 (95%CI 2.4-7.1)] and not receiving anti-TNF at the time of dilation [OR 1.7 (95% CI 1.1-2.6)] were independently related to therapeutic success per dilation. A stricture length ≤ 2 cm [HR 2.43 (95% CI 1.11-5.31)] was a predictive factor of long-term success per patient. The rate of major complications was 1.3%.

Conclusions: EBD can be performed with similar efficacy and safety in hospitals with differing levels of complexity and it might be a suitable treatment for UC with short stenosis. To achieve a technical success and the short length of the stenosis seem to be critical for long-term therapeutic success.

Keywords: Crohn’s disease; Endoscopic balloon dilation; Inflammatory bowel disease.

PubMed Disclaimer

References

    1. Aliment Pharmacol Ther. 2015 Nov;42(10):1137-48 - PubMed
    1. Clin Gastroenterol Hepatol. 2015 Oct;13(10):1770-5 - PubMed
    1. Aliment Pharmacol Ther. 2007 Dec;26(11-12):1457-64 - PubMed
    1. Endoscopy. 2006 May;38(5):483-7 - PubMed
    1. Gut. 1996 Nov;39(5):684-9 - PubMed

Publication types

LinkOut - more resources